Celadon Pharmaceuticals PLC Publication of Annual Report & Notice of AGM
03 Giugno 2024 - 6:45PM
RNS Regulatory News
RNS Number : 9355Q
Celadon Pharmaceuticals PLC
03 June 2024
Celadon Pharmaceuticals
Plc
("Celadon" or the
"Company")
Publication of Annual Report
and Notice of Annual General Meeting
London, 3 June 2024- Celadon
Pharmaceuticals Plc, a leading UK based pharmaceutical
company focused on the development and supply of natural
cannabis-based medicines, announces
that copies of the 2023 Annual Report and Accounts, together with
its Notice of 2024 Annual General Meeting ("AGM"), were posted to
shareholders today and are available for viewing on the Company's
website www.celadonpharma.com.
The Company will be holding its AGM
at 12 noon on Thursday 27 June 2024 at the offices of Gowling WLG (UK)
LLP, 4 More London Riverside, London SE1 2AU.
Enquiries:
|
Celadon Pharmaceuticals Plc
|
|
|
James Short
Jonathan Turner
|
Via Powerscourt
|
|
|
|
|
Canaccord Genuity Limited (Nominated Adviser and
Broker)
|
|
|
Bobbie Hilliam/Andrew
Potts
|
+44 (0)20 7523 8000
|
|
Global Investment Strategy UK Limited (Joint
Broker)
James Sheehan
|
+44 (0)20 7048 9400
|
|
Powerscourt Group
|
|
|
Sarah MacLeod / Nick Johnson / Sam
Austrums
|
+44 (0)20 7250 1446
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK
based pharmaceutical company focused on the research, cultivation,
manufacturing, and sale of breakthrough cannabis-based medicines.
Its primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabis-based
medicines for other conditions such as autism. Its 100,000 sq. ft
UK facility is EU-GMP approved and comprises indoor hydroponic
cultivation, proprietary GMP extraction and manufacturing and an
analytical and R&D laboratory. Celadon's Home Office licence
allows for the commercial supply of its GMP pharmaceutical cannabis
product. The Group owns an approved clinical trial using cannabis
based medicinal products to treat chronic pain in the UK. Celadon
also has a minority interest in early-stage biopharma Kingdom
Therapeutics which is developing a licensed cannabinoid medicine to
treat children with Autism Spectrum Disorder.
For further information please visit
our website www.celadonpharma.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOASSEFMDELSEDM
Grafico Azioni Celadon Pharmaceuticals (LSE:CEL)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Celadon Pharmaceuticals (LSE:CEL)
Storico
Da Dic 2023 a Dic 2024
